Fluad QIV

January 2019 •
14 pages •
Report ID: 5779954 •
Format: PDF

Summary
Table of contents

Drug Overview
Fluad QIV (CSL) is a subunit, surface antigen-containing seasonal quadrivalent influenza vaccine adjuvanted with MF-59, an oil-in-water emulsion. It contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination. The vaccine was originally developed by Novartis, which divested its influenza vaccines unit to CSL in August 2015. The vaccine is currently in Phase III development in both the US and EU. Based on CSL’s plan to file for regulatory approval for elderly vaccination in the US before the end of 2019, Datamonitor Healthcare expects Fluad QIV to be launched for elderly vaccination in time for the 2020/21 season.

Analyst Outlook
Fluad QIV (MF-59 adjuvanted quadrivalent influenza vaccine; CSL) is the first adjuvanted quadrivalent influenza vaccine (QIV) being developed for seasonal influenza. Its superior efficacy to the standard inactivated influenza vaccines (IIVs) in the elderly is expected to boost its uptake following its anticipated launch in the 2020/21 season in the US and the 2021/22 season in the EU for the elderly.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager

Fluad QIV

Our reports have been used by over 10K customers, including:

Related reports and data

Topics related to Vaccine

Parent Industry